Taysha Gene Therapies (TSHA)
(Delayed Data from NSDQ)
$2.39 USD
+0.09 (3.91%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $2.40 +0.01 (0.42%) 7:58 PM ET
3-Hold of 5 3
F Value A Growth A Momentum B VGM
Industry / Sector Report
Industry : Medical - Generic Drugs
Zacks Industry Rank
Bottom 31% (174 out of 252)Zacks Sector Rank
Top 25% (4 out of 16)Recommendations and Estimates
Company | Industry | SP500 | |
---|---|---|---|
Average Recommendation (1=Buy, 5=Sell) | 1.10 | 1.42 | 9.99 |
Current Quarter Estimate | -0.11 | 1.25 | 60.00 |
Year Ago Quarter Estimate | -0.28 | -4.28 | 52.54 |
Next Quarter Estimate | -0.11 | 1.37 | 61.00 |
Next Year Estimate | -0.46 | 7.08 | 270.00 |
Growth Rates
Company | Industry | SP500 | |
---|---|---|---|
This Year | 59.38 | 21.80 | 17.08 |
Next Year | -17.95 | 11.20 | 8.00 |
Last 5 Years | NA | 0.80 | 8.10 |
Next 5 Years | NA | 8.50 | NA |
Financials
Company | Industry | |
---|---|---|
Price/Earnings (TTM) | NA | 1.64 |
Price/Book (MRQ) | 5.74 | 1.06 |
Price/Cash Flow (MRFY) | NA | 10.01 |
Dividend Yield | 0.00% | 0.00% |
Net Profit Margin (TTM) | -722.06% | NA |
Return on Equity (TTM) | NA | NA |
Debt to Equity (MRQ) | NA | NA |
MRQ = Most Recent Quarter
TTM = Trailing Twelve Months
MRFY = Most Recent Fiscal Year
Note: Company and S&P 500 ratios relating to share price calculated daily; all others calculated weekly or in accordance with company earnings announcement. Industry medians calculated weekly.